Synapse - Bone Marrow Transplant

Results (2971)

Molecular predictors and effectiveness of measurable residual disease (MRD) eradication with chemotherapy and allogeneic stem cell transplantation for acute myeloid leukemia

Meeting Abstract

Stahl, M.; Derkach, A.; Famulare, C.; Cho, C.; Devlin, S.; Farnoud, N.; Menghrajani, K.; Patel, M. A.; Cai, S. F.; Geyer, M. B.; more...
Blood (2020)

Fulltext@MSK | Save

Results of a phase 1 open label dose escalation trial of AB-205 (allogeneic engineered endothelial cell therapy) in adults with lymphoma undergoing high-dose therapy and autologous hematopoietic cell transplantation (HDT-AHCT)

Meeting Abstract

Scordo, M.; Budde, L. E.; Abedi, M.; Mulroney, C.; Fakhri, B.; Pawarode, A.; Dholaria, B.; Kavalerchik, E.; Aggarwal, S. K.; Qazilbash, M. H.; more...
Blood (2020)

Fulltext@MSK | Save

A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)

Meeting Abstract

Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
Blood (2020)

Fulltext@MSK | Save

Secondary graft-versus-host disease (GVHD) prophylaxis with oral proteasome inhibitor ixazomib is associated with low incidence of recurrent, late acute and chronic GVHD and facilitated calcineurin inhibitor taper within the first year post allogeneic stem cell transplantation

Meeting Abstract

Rodriguez, N.; Lee, J.; Flynn, L.; Murray, F.; Devlin, S.; Izquierdo, C. S.; Cho, C.; Dahi, P. B.; Giralt, S. A.; Sauter, C. S.; more...
Blood (2020)

Fulltext@MSK | Save

A Phase II study of isatuximab (SAR650984) (NSC-795145) for patients with previously treated al amyloidosis (SWOG S1702; NCT#03499808)

Meeting Abstract

Parker, T. L.; Rosenthal, A.; Sanchorawala, V.; Landau, H. J.; Campagnaro, E.; Kapoor, P.; Neparidze, N.; Hagen, P.; Sarosiek, S.; Scott, E. C.; more...
Blood (2020)

Fulltext@MSK | Save

A phase 1 single dose escalation study of palifermin administered pre-transplant conditioning in subjects undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation

Meeting Abstract

Ostojic, A.; Holtzman, N. G.; Curtis, L. M.; Shaffer, B. C.; Rubin, J. S.; Hakim, F. T.; Mays, J. W.; Heller, T.; Cowen, E. W.; Werner, S.; more...
Blood (2020)

Fulltext@MSK | Save

A multi-center biologic assignment trial comparing reduced intensity allogeneic hematopoietic cell transplantation to hypomethylating therapy or best supportive care in patients aged 50-75 with advanced myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Meeting Abstract

Nakamura, R.; Saber, W.; Martens, M. J.; Ramirez, A.; Scott, B. L.; Oran, B.; Leifer, E.; Tamari, R.; Mishra, A.; Maziarz, R. T.; more...
Blood (2020)

Fulltext@MSK | Save

Allogeneic hematopoietic cell transplantation (allo-HCT) in T-cell prolymphocytic leukemia (T-PLL): An analysis from the CIBMTR

Meeting Abstract

Murthy, H. S.; Ahn, K. W.; Estrada-Merly, N.; Gowda, L.; Dholaria, B.; Bal, S.; Alkhateeb, H. B.; Jagadeesh, D.; Oran, B.; Nakamura, R.; more...
Blood (2020)

Fulltext@MSK | Save

Cost and healthcare utilization in relapsed/refractory diffuse large B-cell lymphoma: A real-world analysis of Medicare beneficiaries receiving chimeric antigen receptor T-cell vs. autologous and allogeneic hematopoietic cell transplants

Meeting Abstract

Mohammadi, I.; Purdum, A. G.; Wong, A. C.; Schroeder, A.; Kilgore, K. M.; Shah, G. L.
Blood (2020)

Fulltext@MSK | Save

Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
Blood (2020)

Fulltext@MSK | Save